Aspirin use after diagnosis improves survival in older adults with colon cancer: A retrospective cohort study

Journal of the American Geriatrics Society

Volumn 60, Issue 12, 2012, Pages 2232-2236

  Reimers, Marlies S ^a   Bastiaannet, Esther ^a   Van Herk Sukel, Myrthe P P ^b   Lemmens, Valery E P ^c   Van Den Broek, Colette B M ^a   Van De Velde, Cornelis J H ^a   De Craen, Anton J M ^a   Liefers, Gerrit Jan ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b PHARMO INSTITUTE FOR DRUG OUTCOMES RESEARCH   (Netherlands)

^c The Netherlands   (Netherlands)

Author keywords

aspirin; colon cancer; elderly; survival

Indexed keywords

ACETYLSALICYLIC ACID;

AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER REGISTRY; COHORT ANALYSIS; COLON CANCER; COMORBIDITY; FEMALE; FOLLOW UP; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHARMACY; PRESCRIPTION; RETROSPECTIVE STUDY; TUMOR LOCALIZATION;

AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; COLONIC NEOPLASMS; FEMALE; HUMANS; MALE; SURVIVAL RATE;

EID: 84871027434     PISSN: 00028614     EISSN: 15325415     Source Type: Journal    
DOI: 10.1111/jgs.12033     Document Type: Article

References (32)

1. Devon KM, Vergara-Fernandez O, Victor JC, et al. Colorectal cancer surgery in elderly patients: Presentation, treatment, and outcomes. Dis Colon Rectum 2009; 52: 1272-1277.
2. Bastiaannet E, Sampieri K, Dekkers OM, et al. Use of aspirin postdiagnosis improves survival for colon cancer patients. Br J Cancer 2012; 106: 1564-1570.
3. Cunningham D, Atkin W, Lenz HJ, et al. Colorectal cancer. Lancet 2010; 375: 1030-1047.
4. van den Broek CB, Dekker JW, Bastiaannet E, et al. The survival gap between middle-aged and elderly colon cancer patients. Time trends in treatment and survival. Eur J Surg Oncol 2011; 37: 904-912.
5. Andre T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004; 350: 2343-2351.
6. Jessup JM, Stewart A, Greene FL, et al. Adjuvant chemotherapy for stage III colon cancer: Implications of race/ethnicity, age, and differentiation. JAMA 2005; 294: 2703-2711.
7. Sargent DJ, Goldberg RM, Jacobson SD, et al. A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med 2001; 345: 1091-1097.
8. Burn J, Gerdes AM, Macrae F, et al. Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: An analysis from the CAPP2 randomised controlled trial. Lancet 2011; 378: 2081-2087.
9. Rothwell PM, Fowkes FG, Belch JF, et al. Effect of daily aspirin on long-term risk of death due to cancer: Analysis of individual patient data from randomised trials. Lancet 2011; 377: 31-41.
10. Rothwell PM, Price JF, Fowkes FG, et al. Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: Analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet 2012; 379: 1602-1612.
11. Chan AT, Ogino S, Fuchs CS,. Aspirin use and survival after diagnosis of colorectal cancer. JAMA 2009; 302: 649-658.
12. Midgley RS, McConkey CC, Johnstone EC, et al. Phase III randomized trial assessing rofecoxib in the adjuvant setting of colorectal cancer: Final results of the VICTOR trial. J Clin Oncol 2010; 28: 4575-4580.
13. Chen WS, Wei SJ, Liu JM, et al. Tumor invasiveness and liver metastasis of colon cancer cells correlated with cyclooxygenase-2 (COX-2) expression and inhibited by a COX-2-selective inhibitor, etodolac. Int J Cancer 2001; 91: 894-899.
14. Yao M, Zhou W, Sangha S, et al. Effects of nonselective cyclooxygenase inhibition with low-dose ibuprofen on tumor growth, angiogenesis, metastasis, and survival in a mouse model of colorectal cancer. Clin Cancer Res 2005; 11: 1618-1628.
15. van Herk-Sukel MP, van de Poll-Franse LV, Lemmens VE, et al. New opportunities for drug outcomes research in cancer patients: The linkage of the Eindhoven Cancer Registry and the PHARMO Record Linkage System. Eur J Cancer 2010; 46: 395-404.
16. Gasic GJ, Gasic TB, Stewart CC,. Antimetastatic effects associated with platelet reduction. Proc Natl Acad Sci U S A 1968; 61: 46-52.
17. Siironen P, Ristimaki A, Nordling S, et al. Expression of COX-2 is increased with age in papillary thyroid cancer. Histopathology 2004; 44: 490-497.
18. Coghill AE, Newcomb PA, Campbell PT, et al. Prediagnostic non-steroidal anti-inflammatory drug use and survival after diagnosis of colorectal cancer. Gut 2011; 60: 491-498.
19. Din FV, Theodoratou E, Farrington SM, et al. Effect of aspirin and NSAIDs on risk and survival from colorectal cancer. Gut 2010; 59: 1670-1679.
20. Baigent C, Blackwell L, Collins R, et al. Aspirin in the primary and secondary prevention of vascular disease: Collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009; 373: 1849-1860.
21. Algra AM, Rothwell PM,. Effects of regular aspirin on long-term cancer incidence and metastasis: A systematic comparison of evidence from observational studies versus randomised trials. Lancet Oncol 2012; 13: 518-527.
22. Ali R, Toh HC, Chia WK,. The utility of aspirin in Dukes C and high risk Dukes B colorectal cancer-the ASCOLT study: Study protocol for a randomized controlled trial. Trials 2011; 12: 261.
23. Brown JR, DuBois RN,. COX-2: a molecular target for colorectal cancer prevention. J Clin Oncol 2005; 23: 2840-2855.
24. Wang D, DuBois RN,. The role of COX-2 in intestinal inflammation and colorectal cancer. Oncogene 2010; 29: 781-788.
25. Greenhough A, Smartt HJ, Moore AE, et al. The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment. Carcinogenesis 2009; 30: 377-386.
26. Ogino S, Kirkner GJ, Nosho K, et al. Cyclooxygenase-2 expression is an independent predictor of poor prognosis in colon cancer. Clin Cancer Res 2008; 14: 8221-8227.
27. Rodriguez-Moranta F, Castells A,. Mechanisms of colon cancer prevention with and beyond COX-2 inhibition. Curr Top Med Chem 2005; 5: 505-516.
28. Masunaga R, Kohno H, Dhar DK, et al. Cyclooxygenase-2 expression correlates with tumor neovascularization and prognosis in human colorectal carcinoma patients. Clin Cancer Res 2000; 6: 4064-4068.
29. Buchanan FG, Chang W, Sheng H, et al. Up-regulation of the enzymes involved in prostacyclin synthesis via Ras induces vascular endothelial growth factor. Gastroenterology 2004; 127: 1391-1400.
30. Cha YI, DuBois RN,. NSAIDs and cancer prevention: Targets downstream of COX-2. Annu Rev Med 2007; 58: 239-252.
31. Chan TA,. Nonsteroidal anti-inflammatory drugs, apoptosis, and colon-cancer chemoprevention. Lancet Oncol 2002; 3: 166-174.
32. Hanahan D, Weinberg RA,. Hallmarks of cancer: The next generation. Cell 2011; 144: 646-667.